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Abstract
Background: Heliotropium indicum is used as a traditional remedy for hypertension in Ghana. The aim of the study
was to evaluate the anti-glaucoma potential of an aqueous whole plant extract of H. indicum to manage
experimentally-induced glaucoma.
Methods: The percentage change in intraocular pressure (IOP), after inducing acute glaucoma
(15 mLkg−1 of 5 % dextrose, i.v.), in New Zealand White rabbits pretreated with Heliotropium indicum aqueous extract
(HIE) (30–300 mgkg−1), acetazolamide (5 mgkg−1), and normal saline (10 mLkg−1) per os were measured. IOPs were also
monitored in chronic glaucoma in rabbits (induced by 1 % prednisolone acetate drops, 12 hourly for 21 days) after
treatments with the same doses of HIE, acetazolamide, and normal saline for 2 weeks. The anti-oxidant property of the
extract was assessed by assaying for glutathione levels in the aqueous humour. Glutamate concentration in the vitreous
humour was also determined using ELISA technique. Histopathological assessment of the ciliary bodies was made.
Results: The extract significantly reduced intraocular pressure (p≤ 0.05–0.001) in acute and chronic glaucoma, preserved
glutathione levels and glutamate concentration (p≤ 0.01–0.001). Histological assessment of the ciliary body showed a
decrease in inflammatory infiltration in the extract and acetazolamide-treated group compared with the
normal saline-treated group.
Conclusion: The aqueous whole plant extract of Heliotropium indicum has ocular hypotensive, anti-oxidant
and possible neuro-protective effects, which therefore underscore its plausible utility as an anti-glaucoma drug with
further investigation.
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Background
Glaucoma, referred to as the silent thief of sight, is recorded
as the second most important cause of blindness and the
leading cause of irreversible blindness globally [1, 2].
It is said to be a heterogeneous group of diseases result-
ing from multiple causative factors including increase in
intraocular pressure (IOP) and vascular dysregulation.
These factors largely contribute to the initial injury in this
disorder by hindering axoplasmic flow within the retinal
ganglion cell (RGC) axons at the lamina cribrosa, impair-
ing the optic nerve microcirculation at the level of lamina,
and changing the laminar glial and connective tissue [3].
Factors leading to further damage include excitotoxicity
caused by glutamate or glycine that is freed from injured
neurons and oxidative damage [4]. Despite the provision
of appropriate treatment, blindness still occurs in nearly
10 % of sufferers [5]. The most common form of the glau-
comas, primary open angle glaucoma (POAG), presents
with no warning symptoms, especially at its early stages [6].
Ghana is one of the worse affected countries in the
world as it is ranked second after St. Lucia in terms of
glaucoma prevalence [7]. It is also reported to have early
age of onset (30 years) compared to the global trend of
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40 years, with risk factors such as age and ethnicity
[8–10]. The most aggressive form of glaucoma has
been reported among people of African descent and
they are three times more likely to suffer from glau-
coma compared to Caucasians [11]. Cost-of-illness
studies have shown the importance of this disease,
with the United Kingdom spending more than £300 mil-
lion in 2002 on glaucoma prevention and treatment [12].
In the United States, it is the reason for over 10 million
visits to physicians annually, with a yearly estimated cost
of over $1.5 billion to its government [5]. Elsewhere in
Africa where there is reliable data, it is evident that the
middle-class spent more than half their monthly income,
while low-income earners spent virtually all their monthly
take-home salary to treat glaucoma [13]. This makes it an
expensive disease so far as its management is concerned.
Management options for glaucoma include the use of
medicines, as well as lasers and incisional surgery, with
medical therapy being the most common [14]. None of
these management procedures are free of complications,
with some leading to loss of vision instead of its preser-
vation [15, 16]. The development of new treatment op-
tions with minimal side effects is therefore important,
specifically those that target the modifiable pathogenic
factor of ocular hypertension in addition to others.
It is within this context that the current study investi-
gated the anti-glaucoma potential of an aqueous whole
plant extract of Heliotropium indicum L. (Boraginaceae)
also known as cock’s comb to manage experimentally-
induced glaucoma as an initial step in bioprospecting for
treatment options for the disease. In Ghana and elsewhere
in Africa, H. indicum is widely used as a traditional rem-
edy for several diseases such as abdominal pain, convul-
sion, cataract, conjunctivitis, cold and high blood pressure
among others [17, 18]. The plant is prepared and applied
in various forms such as decoction, powder, cold infusion,
poultice, concoction or squeezing its juice onto the
affected area depending on the ailment. In some localities
in Ghana, it is used in preparation of soup for postpartum
women to treat inflammatory reactions. For the purposes
of pressure-lowering effect, preparations of H. indicum
are used orally as a decoction, concoction or as a dietary
ingredient in locally prepared soups.
Methods
Plant collection
Heliotropium indicum was collected in November, 2012,
from the University of Cape Coast botanical gardens
(5.1036° N, 1.2825° W), located in the Central Region of
Ghana. It was identified and authenticated by a botanist
at the School of Biological Sciences, College of Agricul-
tural and Natural Sciences, University of Cape Coast,
Cape Coast, Ghana. A voucher specimen, numbered
4873, has been deposited at the herbarium.
Preparation of the H. indicum aqueous extract (HIE)
Whole plants of H. indicum were washed thoroughly with
tap water and shade-dried. The dried plants were milled into
coarse powder (1.5 kg) by a hammer mill (Schutte Buffalo,
New York, NY), then mixed with 1 liter of water. The mix-
ture was soxhlet extracted at 80 °C, for 24 h, and the aque-
ous extract was freeze-dried (Hull freeze-dryer/lyophilizer
140 SQ, Warminster, PA). The powder obtained (yield
12.2 %), was labelled HIE, and stored at a temperature
of 4 °C. This (HIE) was reconstituted in normal saline
to the desired concentration for dosing in this study.
Drugs and chemicals used
Prednisolone acetate ophthalmic suspension (1 %) (Alcon
Laboratories, Inc. Texas, USA) was used to induce
ocular hypertension. Proparacaine hydrochloride ophthal-
mic solution (Ashford Laboratories Ltd, China Macau) was
used as a local anaesthetic in the eyes during IOP measure-
ments. Acetazolamide (Ernest Chemists Ltd, Tema, Ghana)
was used as the reference anti-glaucoma drug.
Experimental animals and husbandry
Twenty five New Zealand White rabbits, weighing 1.0 ±
0.2 kg, were housed singly in aluminium cages (34 cm ×
47 cm × 18 cm) with soft wood shavings as bedding,
under ambient conditions (temperature 28 ± 2 °C, rela-
tive humidity 60–70 %, and a normal light–dark cycle)
in the Animal House of the School of Biological Sci-
ences, University of Cape Coast, Ghana. They were fed
on a normal commercial pellet diet (Agricare Ltd, Kumasi,
Ghana) and had access to water ad libitum.
Ethical and biosafety considerations
The study protocol was approved by the Institutional Review
Board on Animal Experimentation, Faculty of Pharmacy and
Pharmaceutical Sciences, Kwame Nkrumah University of
Science and Technology, Kumasi, Ghana (Ethical clearance
number: FPPS/PCOL/0030/2013). All activities performed
during the study conformed to acceptable principles on
the use and care of laboratory animal (EU directive of
1986: 86/609/EEC), and the association for research in
vision and ophthalmology statement for use of animals in
ophthalmic and vision research. Biosafety guidelines for pro-
tection of personnel in the laboratory were also observed.
Preliminary phytochemical screening
Screening was performed on HIE to ascertain the presence
of phytochemicals using standard procedures described by
Harborne [19] and Kujur et al. [20].
Assessing hypotensive effect of HIE in an acute glaucoma
model
The basal IOP in each eye of each rabbit was measured
using an improved Schiotz indentation tonometer (J. Sklar
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Manufacturing Company, Long Island City, N.Y), which
was calibrated by an open manometric calibration pro-
cedure as described elsewhere [21]. Care was taken to
prevent the nictitating membrane from coming under
the base of the tonometer. Tension was recorded each
time by two weights (5.5 g and 10 g), and the mean of
the two recordings was calculated. The animals were
then put into five groups (n = 5) labelled A-E. Groups
A, B, and C received 30, 100 and 300 mgkg−1 HIE
respectively, while Groups D and E received 5 mgkg−1
acetazolamide and 10 mLkg−1 normal saline respectively.
All administration was by mouth using an oral gavage.
This was to mimic its ethno-pharmacological use. Each
animal received not more than 1 mL of HIE. After
30 min, 15 mLkg−1 of 5 % dextrose solution was adminis-
tered intravenously, through the marginal ear vein. IOP
measurements were made every 20 min for 120 min in
each eye. The percentage change in IOPs was then deter-
mined by the following formula:
% Change in IOP ¼ IOPt– IOP0= IOP0ð Þ  100
Where IOPt is the ocular tension (at different times)
after dextrose or steroid (prednisolone) administration
and IOPo is the ocular tension before dextrose or steroid
(prednisolone administration (i.e. time zero).
Assessing the hypotensive effect of HIE in a chronic
glaucoma model
a. Induction of ocular hypertension in rabbits
After baseline measurements of IOPs, ocular
hypertension was induced in rabbits by instilling 1 %
prednisolone acetate in each eye, twice daily (12
hourly) for 21 days, while measuring the IOP weekly
(between 8.30 and 9.00 AM). Animals with at least a
50 % increase in IOP and characterized with one or
more of the following clinical signs: bulging eyeball
(buphthalmic eyes), fixed dilated pupils, sluggish
pupillary reaction, and limbal injection [22], were
selected for this study.
b. Assessment of ocular hypotensive effect of HIE
Rabbits with ocular hypertension were divided into
five groups labelled I-V. Each group was treated orally,
twice daily (12 hourly), with 30, 100, 300 mgkg-1 HIE,
5 mgkg−1 Acetazolamide (positive control), or 10 ml/kg
normal saline (negative control), for 2 weeks with
intraocular pressure measurements being made in
each eye every other day for the same period.
Determination of glutathione in aqueous humour
Total glutathione in the aqueous humour of the experi-
mental animals was determined using a commercial kit
(Cayman Chemicals, Ann Arbor, MI, USA). The animals
were euthanized and the anterior chamber punctured
with a 30-gauge needle. The aqueous humour was
collected from both eyes and stored in sterile eppendorf
tubes. The aqueous humour was then deproteinated
using metaphosphoric acid and 4 M triethanolamine ac-
cording to the manufacturer’s instruction. A 50 μL vol-
ume of the deproteinated aqueous humour and the
standards (constituted per the manufacturer’s directive)
were pipetted into a 96 well plate, incubated in the dark
on an orbital shaker, and read at 405 nm using a URIT-660
microplate reader (URIT Medical Electronic Co., Ltd,
Guangxi, China). Each determination was performed in
duplicates.
Evaluation of glutamate in vitreous humour
Glutamate concentration in the vitreous humour of
experimental animals was determined using the glutam-
ate assay kit. The vitreous humour in each eye was col-
lected in separate sterile eppendorf tubes after accessing
it through a scleral puncture at the lateral canthus. The
vitreous bodies were sonicated in 0.2 M perchloric acid
containing 0.1 % Na2S205 and 0.1 % EDTA. Homogenates
were centrifuged at l5,000 g for 5 min at 4 °C and the super-
natant were used for the glutamate concentration assay. The
samples and standards were prepared according to manu-
facturer’s instructions, pipetted into a 96 well microplate,
and read at 405 nm using the URIT-660 microplate reader
(URIT Medical Electronic Co., Ltd, Guangxi, China). Each
determination was performed in triplicates.
Histopathological assessment
The enucleated eyes of the animals were fixed in 10 %
phosphate-buffered paraformaldehyde, and embedded in
paraffin for histopathological assessment. Sections were
made and stained with haematoxylin and eosin and
alcian blue [23]. Sections were fixed on glass slides for
microscopic examination by a specialist pathologist at
the Pathology Department of the Komfo Anokye Teaching
Hospital, Kumasi, Ghana.
Statistical analysis
Results were analysed using one-way analysis of variance
followed by Dunnett’s multiple comparisons test using
GraphPad Prism (version 5.03; GraphPad, La Jolla, CA).
Values were expressed as the mean ± standard error of the
mean and p ≤ 0.05 was considered statistically significant.
Results
HIE pretreatment significantly (p ≤ 0.001) prevented the
expected rise in IOP in dextrose-induced ocular hyper-
tension compared to the normal saline pre-treated rab-
bits (Fig. 1); the effect was comparable to acetazolamide
pretreatment (p ≤ 0.001) as there was no significance
(p > 0.05) in the IOP lowering effect of acetazolamide
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and HIE. Similarly, oral treatments of steroid-induced
ocular hypertension with HIE showed a significant
(p ≤ 0.05–0.001) reduction in IOPs of the right and
the left eyes of the rabbits vs. normal saline treated
animals (Fig. 2). Effects were comparable (p ≤ 0.001)
to acetazolamide treatment.
Level of glutathione in aqueous humour
The HIE and acetazolamide treatments in the chronic
model of glaucoma studies significantly (p ≤ 0.01–0.001)
reduced oxidative stress by preserving aqueous endogen-
ous glutathione levels (Table 1).
Concentration of glutamate in Vitreous humour
Treatment with HIE and acetazolamide caused a signifi-
cant (p ≤ 0.01–0.001) reduction of excitotoxin in the vit-
reous humour of the ocular hypertensive treated animals
(Table 1).
Histopathological assessment
The histopatological assessment of the structures of the
anterior chamber did indicate relatively reduced signs of
morphological changes in ciliary bodies of all rabbits
treated with HIE, and acetazolamide. However, there were
histopathological signs of tissue alteration characterized
by mononuclear infiltration into the ciliary body (Fig. 3).
Discussion
Glaucoma is described as an assemblage of ocular disor-
ders with multi-factorial causes united by a clinically char-
acteristic optic neuropathy with or without a rise in
intraocular pressure (IOP). As it is not a single disease
entity, it is sometimes referred to as “the glaucomas” [3]
for which IOP reduction remains the only evidence-based
treatment approach. Experimental glaucoma is a model that
mimics the human condition, and is very useful in studies
aimed at understanding the pathophysiology of the disease
and in pre-clinical studies of potential anti-glaucoma
agents [24].
Acute glaucoma was induced in rabbits using 5 %
dextrose administered intravenously; this method has
obvious advantages over the water-loading model [25].
Intravenously administered dextrose lowers serum osmo-
larity after the sugar has been cleared from circulation.
This reduced serum osmolarity leads to the movement of
water into the eye thereby increasing IOP [24, 25]. Pre-
treatment with the extract prevented the expected rise in
IOP (p ≤ 0.001) compared to the normal saline pretreated
Fig. 1 Time-course curves and areas under the curve for the for acute glaucoma study. Time-course curves (a & c) and areas under the curve
(b & d) for the effects of pretreatment with 30, 100, and 300 mgkg−1 of HIE, 5 mgkg−1 Acetazolamide (ACET), and 10 mLkg−1 normal saline (NS)
on Dextrose-induced ocular hypertension of the right eye (a, b) and left eye (c, d) in New Zealand White Rabbits. Values plotted represent
mean ± SEM (n = 5). ***p ≤ 0.001, ANOVA followed by Dunnett’s post-hoc test
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group, indicating that the extract could be acting by redu-
cing aqueous humour production or increasing outflow
facility [26]. A previous study that assessed the hypotensive
effect of H. indicum extract on systemic hypertension
indicated that it exerts its hypotensive effect via
muscarinic receptor stimulation [27], implying that its
ocular hypotensive effect could be due to enhanced
outflow facility rather than reduced aqueous humour
production. Again, an important relation has been found
between systemic blood pressure and the development of
glaucoma. That is, an increased blood pressure as in the
case of hypertension impairs autoregulation of blood flow,
which consequentially affects blood circulation to the
optic nerve inducing glaucoma via ischemic tendencies
[28]. On the other hand, hypotension has also been
named as a risk factor for glaucoma therefore, further
studies would be needed to ascertain the clinical ap-
plication of HIE in glaucoma management as it has
been reported to reduce blood pressure in some studies
48.25 ± 3.56 % [27, 29].
The anti-glaucoma potential of HIE was further sub-
stantiated by testing its ocular hypotensive effect on a
more sustained (chronic) model of ocular hypertension.
The corticosteroid–induced model bears semblance of
POAG, and is characterized by aqueous outflow obstruc-
tion, optic nerve cupping and visual field defects [22, 30].
HIE treatment reduced (p ≤ 0.05–0.001) the IOP induced
by steroid pretreatment in the rabbits. A recent study
showed that POAG, as modelled by corticosteroid-induced
ocular hypertension in rabbits, is a multi-tissue disease
entity involving the trabecular meshwork, the optic
nerve head, the lateral geniculate nuclei, and the visual
cortex. Stressors such as repeated steroid intake triggers
oxidative stress resulting in compromised aqueous humour
antioxidant system and apoptotic trabecular meshwork cell
loss. This apoptotic cell loss is informed by severe mito-
chondrial damage altering tissue function and integrity
[31]. The extract could therefore be exerting its ocular
hypotensive effect via improving aqueous outflow, protec-
tion of the structural integrity of the trabecular meshwork
or both [31]. The reference drug, acetazolamide, on the
Fig. 2 Time-course curves and areas under the curve for the for chronic glaucoma study. Time-course curves (a & c) and areas under the curve
(b & d) for the effects of treatment with 30, 100, and 300 mgkg−1 of HIE, 5 mgkg−1 Acetazolamide (ACET), and 10 mLkg−1 normal saline (NS) on
steroid-induced ocular hypertension of the right eye (a, b) and left eye (c, d) in New Zealand White Rabbits. Values plotted represent mean ± SEM
(n = 5). ***p≤ 0.001, **p ≤ 0.01, *p ≤ 0.05. ANOVA followed by Dunnett’s post-hoc test
Table 1 Total glutathione (GSH) in the aqueous humour and
glutamate levels in the vitreous of controls and HIE-treated
chronic ocular hypertensive New Zealand White Rabbits
Treatment GSH (μM) Glutamate (nmol)
Normal Saline 3.703 ± 0.437 8.650 ± 0.203
Acetazolamide 11.52 ± 1.171*** 7.383 ± 0.130***
30 mgkg−1 HIE 10.19 ± 0.632*** 6.850 ± 0.092***
100 mgkg−1 HIE 7.507 ± 0.760** 7.767 ± 0.010**
300 mgkg−1 HIE 11.23 ± 0.316*** 6.033 ± 0.257***
Values represent mean ± SEM (n = 5). **p ≤ 0.01, ***p ≤ 0.001, one-way analysis
of variance followed by Dunnett’s post hoc test
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other hand, is a specific carbonic anhydrase inhibitor that
lowers the intraocular pressure of mammal’s eyes by
partially inhibiting aqueous humour formation [32]. In
addition to the inhibition of aqueous production, it has
been reported to also decrease oxidative damage of the tra-
becular meshwork and more so in the presence of active
mitochondria [33]. Mitochondria are predicted as the key
intracellular target for most drugs with antioxidant proper-
ties [34]. This is suggestive of the possibility of multiple
mechanistic pathways in exerting their therapeutic effect.
Acetazolamide is one of the few medications that exist in
both oral and topical forms that are effective in reducing
IOP and improving retinal blood flow [35]. Its oral formula-
tion affords ophthalmic caregivers the options of achieving
greater bioavailability (oral bioavailability of more than
90 %) for aggressive forms of glaucoma when the short
precorneal residence time poses the challenge of poor
bioavailability upon topical application [36]. However,
oral doses of acetazolamide are associated with a myr-
iad of systemic side effects due to the wide distribution
of the carbonic anhydrase enzyme, which has many
functions including transporting CO2 from the tissues
to the lung, excreting and reabsorbing electrolytes and
H+ ions in the kidney, secreting H+ ions into the gas-
tric mucosa, and maintaining the major buffer system
of the human body [37, 38]. Preliminary data from our
laboratory indicates that topical application of HIE
into the conjunctival cul-de-sac is safe, but medium
term oral (subchronic) usage of therapeutic doses pro-
duced subtle morphometric changes in the liver, kidney
Fig. 3 Photomicrographs of the anterior chamber of ocular hypertensive rabbits per the various treatments. Photomicrograph of anterior chamber of
rabbits (H and E × 100), (a) glaucomatous rabbit with 10 mlkg−1 normal saline treatment (Control) showing intense neutrophilic infiltration in the ciliary
body, (b) glaucomatous rabbit with 5 mgkg−1 Acetazolamide treatment. Normal marginal zone of the ciliary process with normal architecture is shown,
(c) glaucomatous rabbit with 30 mgkg−1 HIE treatment indicating moderate neutophilic infiltration in the cilairy body, (d) Glaucomatous rabbit with 100
mgkg−1 HIE treatment indicating mild neutophilic infiltration and (e) glaucomatous rabbit with 300 mgkg−1 HIE treatment. There is moderate oedema of
the cliary body
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and the spleen upon histological assessment. Further stud-
ies are still ongoing in this regard.
It is clear that oxidative stress, which is an important
etiologic factor in the pathogenesis of glaucoma, [39] is
manly driven by free radicals in living systems when
endogenous antioxidant defences are deficient [40]. It is
proven in humans that both elevated IOP and visual
field loss are notably related to the amount of oxidative
DNA damage affecting trabecular meshwork (TM) cells,
thereby affecting outflow facility [41]. Glutathione has
been found in significant proportions in the aqueous
humour and plays an essential role in defending the
system against oxidative stress-provoked diseases [42].
The antioxidant statuses of biological samples are there-
fore useful as a marker of oxidative stress [43]. The ex-
tract treatment preserved endogenous aqueous humour
glutathione levels (p ≤ 0.01–0.001), which suggests its
usefulness not only in reducing IOP, but also in providing
a protection against oxidative damage critical in advancing
the progression of glaucomatous neurodegeneration. This
presupposes that the HIE targets mitochondrial cells of
the trabecular meshwork in exerting its effect.
Excitotoxicity elicited by the amino acid glutamate is
gaining attention so far as the mediation of neuronal
death in many disorders. An understanding of excito-
toxic injury provides clues in the search for answers to
such fundamental questions such as the continual loss
of retinal ganglion cells despite achieving IOP control
[44]. Amidst the ranging controversy over its pathogenic
role in glaucoma [45, 46], there was an observed reduc-
tion of glutamate concentration (p ≤ 0.01–0.001) in the
extract-treated rabbits. Studies have shown that vitreous
is easily obtainable and remains an important biological
sample in postmortem analysis, in that it is less prone to
putrefaction and contamination relative to other body
fluids as postmortem biochemical changes occur more
slowly in the eye [47]. The hypothesized association
between glutamate excitotoxicity and neurological disor-
ders such as glaucoma was well managed by the HIE
treatment [48, 49].
Histopathological changes were remarkable in the anter-
ior chamber of normal saline treated animals but relatively
minimal in the extract-treated and the acetazolamide-
treated rabbits. Glaucoma is exceptional amongst ocular
disorder in that its principal pathophysiology involves
structures in both the anterior and posterior segments of
the eye. This affords the option of tracking pathological
changes in either segment or both [23].
The extract owes its net anti-glaucoma potential effect
to the synergistic effect of its phytochemicals acting
concomitantly on the diverse etiologic factors. Other
researchers have established that some alkaloids possess
hypotensive effect more particularly via muscarinic action
[50]. Saponins have also been demonstrated to have some
hypotensive activity [51]. Flavonoids, in general, have been
proven to possess antioxidant activity relevant for free
scavenging activity that is necessary to preserve the eye’s
endogenous antioxidant system [52]. This cocktail of bio-
active compounds detected in HIE affirms the mechanistic
multiplicity of its therapeutic effect in experimental glau-
coma management.
Conclusion
The aqueous whole plant extract of H. indicum exhibits
ocular hypotensive, antioxidant and potential neuropro-
tective effects hence, it could be a useful anti-glaucoma
drug with further studies.
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